Literature DB >> 20216239

Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?

Ulrike Leiter1, Petra G Buettner, Thomas K Eigentler, Andrea Forschner, Friedegund Meier, Claus Garbe.   

Abstract

Surveillance schedules in patients with cutaneous melanoma (CM) aim to detect metastatic spread in an early phase of development. Few studies investigated whether detection in an early phase is associated with prolonged survival and whether the observed longer survival times are a mere consequence of detection at an earlier time point (lead time bias). This is a long-term survival analysis of 1969 patients with stage I-III CM documented during 1996-1998 in the frame of a prospective surveillance study. Development of metastatic spread was detected in 112 patients during this period and classified as early phase or advanced phase based on tumor load and operability. The impact of lead time bias on differences in survival probabilities was examined using different statistical approaches. Of 59 patients with metastases detected in an early phase of development, 64.4% died of CM, of 43 patients with advanced phase metastases 86% died (P=0.013). The 10-year overall survival probability was 42.6% for early and 25.6% for advanced phase metastases (P=0.012). This comparison remained significant after adjustment for sojourn time. Multivariate analysis identified detection of early phase metastases (P=0.022) and stage at primary diagnosis (P<0.0001) as independent prognostic factors. In conclusion, this long-term follow-up study showed a factual gain in survival time for the detection of metastasis in an early phase of development beyond lead time bias. The classification of metastasis detected in early and advanced phase may be used in future studies aiming to improve melanoma surveillance.

Entities:  

Mesh:

Year:  2010        PMID: 20216239     DOI: 10.1097/CMR.0b013e32833716f9

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  14 in total

Review 1.  Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review.

Authors:  Maria Danielsen; Liselotte Højgaard; Andreas Kjær; Barbara Mb Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

2.  The role of routine imaging in pediatric cutaneous melanoma.

Authors:  Hadeel Halalsheh; Sue C Kaste; Fariba Navid; Armita Bahrami; Barry L Shulkin; Bhaskar Rao; Michelle Kunkel; Nathan Artz; Alberto Pappo
Journal:  Pediatr Blood Cancer       Date:  2018-08-19       Impact factor: 3.167

3.  Randomized controlled trial of the mySmartSkin web-based intervention to promote skin self-examination and sun protection behaviors among individuals diagnosed with melanoma: study design and baseline characteristics.

Authors:  Elliot J Coups; Sharon L Manne; Pamela Ohman Strickland; Michelle Hilgart; James S Goydos; Carolyn J Heckman; Paola Chamorro; Babar K Rao; Moira Davis; Franz O Smith; Frances P Thorndike; Lee M Ritterband
Journal:  Contemp Clin Trials       Date:  2019-06-27       Impact factor: 2.226

4.  18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma.

Authors:  Zachary J Jaeger; Gregory A Williams; Ling Chen; Joyce C Mhlanga; Lynn A Cornelius; Ryan C Fields
Journal:  J Surg Oncol       Date:  2021-11-06       Impact factor: 3.454

Review 5.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 6.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

Review 7.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

8.  Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Authors:  Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.

Authors:  Barbara Peric; Ivana Zagar; Srdjan Novakovic; Janez Zgajnar; Marko Hocevar
Journal:  BMC Cancer       Date:  2011-08-02       Impact factor: 4.430

10.  Serum microRNAs as biomarkers for recurrence in melanoma.

Authors:  Erica B Friedman; Shulian Shang; Eleazar Vega-Saenz de Miera; Jacob Ulrik Fog; Maria Wrang Teilum; Michelle W Ma; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Eva Hernando; Adam Baker; Yongzhao Shao; Iman Osman
Journal:  J Transl Med       Date:  2012-08-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.